Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma
Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma
批准号:
10612251
负责人:
Michael Jackson
金额:
$48.75万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-15 至 2023-04-30
关键词:
AffectAntineoplastic AgentsBioinformaticsBiological AssayBiological MarkersBromodomainCell SurvivalCellsChemicalsChemotherapy and/or radiationChildChildhoodChildhood Brain NeoplasmChildhood MedulloblastomasCollectionDataDevelopmentDiagnosisDiseaseExhibitsFrequenciesGene ExpressionGenetic MarkersGenetic TranscriptionGenomicsGoalsHourHumanIncidenceInduced pluripotent stem cell derived neuronsLeadLibrariesMYC Family ProteinMYC geneMalignant NeoplasmsMalignant neoplasm of cerebellumMetabolicMolecular ProfilingMonitorMusMutationOncoproteinsOperative Surgical ProceduresPatient-Focused OutcomesPatientsPermeabilityPharmaceutical ChemistryPhasePhenotypePropertyProtein phosphataseRadiationRecurrenceRouteSHH geneSamplingSeriesSolubilityStructure-Activity RelationshipSubgroupSurvival RateSurvivorsTestingTherapeuticTherapeutic AgentsTimeToxic effectanalogaurora kinase Abiomarker signatureblood-brain barrier penetrationc-myc Geneschemotherapydesigndrug discoverydruggable targeteffective therapyexperimental studyimmunohistochemical markersimprovedin vivoin vivo evaluationinhibitorlead optimizationmedulloblastomamolecular markermouse modelnovelnovel therapeuticsoverexpressionpatient derived xenograft modelpharmacokinetics and pharmacodynamicspre-clinicalprotein activationscaffoldscale upside effectsmall moleculetargeted treatmenttherapeutically effectivetreatment grouptumortumor growth
中文摘要
项目摘要
髓母细胞瘤(MB)是一种高度恶性的小脑肿瘤,最常见于儿童。
尽管在治疗方面取得了进展-包括手术,放疗和化疗-大约三分之一的人
MB患者仍然死于这种疾病,幸存者由于治疗而遭受严重的副作用。基因组
对患者样本的分析和生物信息学分析已经确定了四个亚组的MB-WNT,Sonic
刺猬(SHH),第3组(MYC驱动)和第4组。这些亚组在突变、基因
表达谱和患者结果,并且患者可以使用相关的遗传和
免疫组织化学标记物。大约四分之一的MB是第3组(G3)肿瘤,其表现出
c-Myc(MYC)癌基因的过度表达或扩增。G3 MB患者更有可能出现
在诊断时有转移性疾病,复发率较高,生存率最差。
因此,迫切需要更有效的G3 MB疗法。
为了鉴定在G3 MB中有效的MYC抑制剂,我们开发了一种表型、靶标不可知的测定方法,
使用分离自G3 MB原位患者来源的异种移植物(PDX)的疾病相关细胞。该测定
旨在鉴定降低内源性MYC水平的小分子-MYC的标志性分子标志物,
G3 MB -在4小时内,优先调节直接影响MYC稳定性的靶点,避免间接或关闭
在以后时间点的目标效果。我们应用该试验筛选了100,000种化合物,
小分子支架,其稳健地降低细胞MYC水平。命中率在严格的测试中得到验证
漏斗设计,以避免不希望的作用机制,并探讨了几个支架的初始SAR。
从这些研究中,最有希望的系列也优先考虑在100 nM效价范围内的活性
作为指示良好BBB渗透的化合物性质。我们进一步证实,
在暴露48小时后,一系列的细胞活力降低,并且这种效应与MYC中的效力相关
比色法该系列中最具活性的化合物SBI 1242的初步数据表明,这种细胞凋亡的减少,
G3 MB患者细胞的存活率相对于iPSC衍生的神经元是选择性的,这表明可能的治疗窗口。
该提案的目标是进一步优化SBI 1242用于临床前体内测试,并使用最佳类似物
测试我们的假设,即在高度疾病相关的疾病中鉴定的G3 MB签名生物标志物MYC的抑制剂,
上下文可以安全有效地阻止或逆转我们的G3 MB特异性原位PDX小鼠中的肿瘤生长
模型我们预计,这些研究的成功完成将是我们朝着长远目标迈出的重要一步。
目标是为MB和其他MYC驱动的癌症确定新的,安全的和有效的治疗方法。
英文摘要
PROJECT SUMMARY
Medulloblastoma (MB) is a highly malignant tumor of the cerebellum that occurs most frequently in children.
Despite advances in treatment – including surgery, radiation, and chemotherapy – approximately one-third of
MB patients still die from the disease and survivors suffer severe side effects as a result of treatment. Genomic
profiling and bioinformatic analyses of patient samples have identified four subgroups of MB – WNT, Sonic
hedgehog (SHH), Group 3 (MYC-driven) and Group 4. These subgroups differ in terms of mutations, gene
expression profiles and patient outcomes, and patients can be stratified using relevant genetic and
immunohistochemical markers. Approximately one-quarter of MBs are Group 3 (G3) tumors, which exhibit
overexpression or amplification of the c-Myc (MYC) oncogene. Patients with G3 MB are more likely to present
with metastatic disease at time of diagnosis, have a higher incidence of recurrence and the poorest survival rate.
Thus, more effective therapies for G3 MB are critically needed.
To identify MYC inhibitors that would be effective in G3 MB, we developed a phenotypic, target-agnostic assay
using disease-relevant cells isolated from G3 MB orthotopic patient-derived xenografts (PDXs). The assay was
designed to identify small molecules that reduce endogenous MYC levels – the signature molecular marker of
G3 MB – in 4 hours, to preferentially modulate targets directly affecting MYC stability and avoid indirect or off-
target effects at later time points. We applied this assay to screen a 100,000 compound collection and identified
small molecule scaffolds that robustly decrease cellular MYC levels. Hits were validated in a rigorous testing
funnel designed to avoid undesired mechanisms of action, and initial SAR was explored for several scaffolds.
From these studies the most promising series was prioritized with activities in the 100 nM potency range as well
as compound properties indicative of good BBB penetration. We further confirmed that the compounds in this
series decrease cell viability after 48 hours exposure and that this effect correlates with potency in the MYC
assay. Preliminary data for the most active compound of this series, SBI1242, indicate that this decrease in cell
viability of G3 MB patient cells is selective over iPSC-derived neurons, suggesting a possible therapeutic window.
The goal of this proposal is to further optimize SBI1242 for preclinical in vivo testing and use the best analog to
test our hypothesis that inhibitors of the G3 MB signature biomarker MYC identified in a highly disease-relevant
context can safely and effectively arrest or reverse tumor growth in our G3 MB-specific orthotopic PDX mouse
model. We anticipate that successful completion of these studies will be a significant step towards our long-term
goal of identifying novel, safe, and effective treatments for MB and other MYC-driven cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
-
批准号:10677899
-
项目类别:
-
资助金额:$77.22万
-
财政年份:2023
-
负责人:Michael Jackson
-
依托单位:
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse
-
批准号:10517225
-
项目类别:
-
资助金额:$215.1万
-
财政年份:2022
-
负责人:Michael Jackson
-
依托单位:
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
-
批准号:10343473
-
项目类别:
-
资助金额:$88.57万
-
财政年份:2022
-
负责人:Michael Jackson
-
依托单位:
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
-
批准号:10581565
-
项目类别:
-
资助金额:$85.31万
-
财政年份:2022
-
负责人:Michael Jackson
-
依托单位:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
-
批准号:10183333
-
项目类别:
-
资助金额:$87.6万
-
财政年份:2020
-
负责人:Michael Jackson
-
依托单位:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
-
批准号:10400863
-
项目类别:
-
资助金额:$90.73万
-
财政年份:2020
-
负责人:Michael Jackson
-
依托单位:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
-
批准号:10595660
-
项目类别:
-
资助金额:$87.17万
-
财政年份:2020
-
负责人:Michael Jackson
-
依托单位:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
-
批准号:10037550
-
项目类别:
-
资助金额:$93.69万
-
财政年份:2020
-
负责人:Michael Jackson
-
依托单位:
Developing Choroid Plexus-Based Tools and Drug Screens
-
批准号:9304373
-
项目类别:
-
资助金额:$24.19万
-
财政年份:2016
-
负责人:Michael Jackson
-
依托单位:
Administrative Core
-
批准号:8379692
-
项目类别:
-
资助金额:$104.47万
-
财政年份:2012
-
负责人:Michael Jackson
-
依托单位:
Sanford-Burnham Center for Chemical Genomics
-
批准号:8336979
-
项目类别:
-
资助金额:$750.0万
-
财政年份:2008
-
负责人:Michael Jackson
-
依托单位:
Chemical Library Screening
-
批准号:10400714
-
项目类别:
-
资助金额:$19.94万
-
财政年份:1997
-
负责人:Michael Jackson
-
依托单位:
Chemical Library Screening
-
批准号:10686139
-
项目类别:
-
资助金额:$19.94万
-
财政年份:1997
-
负责人:Michael Jackson
-
依托单位:
Chemical Library Screening
-
批准号:10174819
-
项目类别:
-
资助金额:$19.94万
-
财政年份:1997
-
负责人:Michael Jackson
-
依托单位:
海外基金